Literature DB >> 35641643

Recent advances on applications of immunosensing systems based on nanomaterials for CA15-3 breast cancer biomarker detection.

Ika Kustiyah Oktaviyanti1, Diyar Salahuddin Ali2, Sura A Awadh3, Maria Jade Catalan Opulencia4, Shukhrat Yusupov5,6, Rui Dias7, Fahad Alsaikhan8, Mais Mahmood Mohammed9, Himanshu Sharma10, Yasser Fakri Mustafa11, Marwan Mahmood Saleh12.   

Abstract

Breast cancer is one of the leading causes of death and is the most routine form of cancer in women in the world. Carbohydrate antigen 15-3 (CA15-3) tumor marker is a serum-based product of the MUC1 gene and different studies have determined the over-regulation of this tumor marker in breast cancer. Moreover, CA15-3 is overexpressed in a number of other types of cancers including lung, ovarian, pancreatic, and colon. The important role of CA-15-3 detection in the screening and diagnosis of breast cancer is proved. Some specific methods for the detection of CA15-3 have significant advantages and also suffer from some disadvantages. Biosensor tools as analytical devices measure biological or chemical reactions, by converting them into electrical signals. Biosensors based on antibody molecules as the detector are called immunosensors. Different types of immunosensors including electrochemical, various optical sensors such as fluorescent, SPR, and colorimetric with immobilization of nanomaterials for improving sensitivity and antibodies can be useful devices for the detection of CA15-3 biomarkers. In this review, we intend to focus on various new immunosensors to overcome the disadvantages of conventional methods for the detection of CA15-3 biomarkers.
© 2022. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  CA15-3; Carbohydrate antigen 15–3; Electrochemical; Fluorescent; Immunosensor; Optical; Surface plasmon resonance

Year:  2022        PMID: 35641643     DOI: 10.1007/s00216-022-04150-z

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  65 in total

1.  Value of CA 15-3 determination in the initial management of breast cancer patients.

Authors:  S Chourin; D Georgescu; C Gray; C Guillemet; A Loeb; C Veyret; J-P Basuyau
Journal:  Ann Oncol       Date:  2009-03-19       Impact factor: 32.976

Review 2.  CA 15-3: uses and limitation as a biomarker for breast cancer.

Authors:  Michael J Duffy; Denis Evoy; Enda W McDermott
Journal:  Clin Chim Acta       Date:  2010-09-08       Impact factor: 3.786

3.  The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.

Authors:  F Safi; I Kohler; E Röttinger; H Beger
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

4.  One-Step Synthesis of Methylene Blue-Encapsulated Zeolitic Imidazolate Framework for Dual-Signal Fluorescent and Homogeneous Electrochemical Biosensing.

Authors:  Jiafu Chang; Wenxin Lv; Qian Li; Haiyin Li; Feng Li
Journal:  Anal Chem       Date:  2020-06-12       Impact factor: 6.986

5.  Aptamer and 5-fluorouracil dual-loading Ag2S quantum dots used as a sensitive label-free probe for near-infrared photoluminescence turn-on detection of CA125 antigen.

Authors:  Hui Jin; Rijun Gui; Jun Gong; Wenxue Huang
Journal:  Biosens Bioelectron       Date:  2016-11-02       Impact factor: 10.618

6.  High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer.

Authors:  Michael J Duffy; Catherine Duggan; Rachel Keane; Arnold D K Hill; Enda McDermott; John Crown; Niall O'Higgins
Journal:  Clin Chem       Date:  2004-01-15       Impact factor: 8.327

7.  Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women.

Authors:  E R Richards; P L Devine; R J Quin; J D Fontenot; B G Ward; M A McGuckin
Journal:  Cancer Immunol Immunother       Date:  1998-07       Impact factor: 6.968

8.  High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC).

Authors:  María Moreno; Hetty J Bontkes; Rik J Scheper; Peter Kenemans; René H M Verheijen; Silvia von Mensdorff-Pouilly
Journal:  Cancer Lett       Date:  2007-08-09       Impact factor: 8.679

9.  Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.

Authors:  D F Hayes; H Sekine; T Ohno; M Abe; K Keefe; D W Kufe
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

10.  A review of breast cancer awareness among women in India: Cancer literate or awareness deficit?

Authors:  A Gupta; K Shridhar; P K Dhillon
Journal:  Eur J Cancer       Date:  2015-07-29       Impact factor: 9.162

View more
  1 in total

Review 1.  Point-of-care electrochemical testing of biomarkers involved in inflammatory and inflammatory-associated medical conditions.

Authors:  Diana-Gabriela Macovei; Maria-Bianca Irimes; Oana Hosu; Cecilia Cristea; Mihaela Tertis
Journal:  Anal Bioanal Chem       Date:  2022-09-14       Impact factor: 4.478

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.